Document is current
Any future updates will be listed below
-
Authors
Chen, Junren https://orcid.org/0000-0003-3691-4931
Cao, Yigeng https://orcid.org/0000-0002-9097-8103
Feng, Yahui
Qi, Saibing
Yang, Donglin https://orcid.org/0000-0002-8567-894X
Hu, Yu
Pang, Aiming
Shen, Qiujin
Luo, Jieya
Gong, Xiaowen
Zhang, Rongli
Zhai, Xiaolin
Li, Xueqian
Yan, Wen
Zhang, Xianjing
Chen, Mengyun
Niu, Mingming
Wei, Jialin
Liang, Chen
Zhai, Weihua
Zhao, Ningning
Liu, Xueou
Liu, Sichang
Zhai, Wangsong
Li, Ruixin
Shao, Xianfeng
Zhang, Dong https://orcid.org/0000-0001-5551-9721
Wang, Mingyang
Pan, Pan
Xu, Mingyue
Zhang, Wei
Xu, Yunqiang
Zhu, Xiaofan https://orcid.org/0000-0002-2572-6495
Guo, Ye
Wang, Hong https://orcid.org/0000-0002-6215-6348
Song, Zhen
Gale, Robert Peter
Han, Mingzhe https://orcid.org/0000-0002-1720-6799
Feng, Sizhou https://orcid.org/0000-0002-8587-3446
Jiang, Erlie https://orcid.org/0000-0003-0237-6063
- License Information
-
More Information
Article History
Received: 18 March 2025
Accepted: 1 August 2025
First Online: 25 September 2025
Competing interests
: RPG is a consultant to Antengene Biotech LLC and Shenzhen TargetRx; Medical Director, FFF Enterprises Inc.; a speaker for Janssen Pharma, BeiGene, and Hengrui Pharma; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board, StemRad Ltd. The remaining authors declare no competing interests.
